Nevertheless, the potential utility of the Erlotinib+TTI‐101 combination therapy for the treatment of ERG‐overexpressing PCa can broaden the first‐line therapeutic approaches currently available for early‐stage PCa, which requires further investigation. Here, ERG is linked to posterior cortical atrophy.